Research programme: cancer therapeutics - Actelion
Latest Information Update: 11 Oct 2007
At a glance
- Originator Actelion Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 11 Oct 2007 Preclinical development is ongoing
- 11 Mar 2004 Preclinical trials in Cancer in Switzerland (unspecified route)